Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Non Operating Income: 2013-2025

Historic Non Operating Income for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $2.1 million.

  • Coherus Oncology's Non Operating Income rose 2.74% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 65.32%. This contributed to the annual value of $3.4 million for FY2024, which is 38.33% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Non Operating Income is $2.1 million, which was down 26.20% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Non Operating Income ranged from a high of $2.9 million in Q2 2025 and a low of -$3.0 million during Q4 2024.
  • In the last 3 years, Coherus Oncology's Non Operating Income had a median value of $1.7 million in 2023 and averaged $1.3 million.
  • As far as peak fluctuations go, Coherus Oncology's Non Operating Income tumbled by 6,516.67% in 2021, and later skyrocketed by 5,300.00% in 2023.
  • Quarterly analysis of 5 years shows Coherus Oncology's Non Operating Income stood at -$385,000 in 2021, then surged by 621.56% to $2.0 million in 2022, then plummeted by 106.42% to -$129,000 in 2023, then plummeted by 2,262.02% to -$3.0 million in 2024, then grew by 2.74% to $2.1 million in 2025.
  • Its Non Operating Income stands at $2.1 million for Q3 2025, versus $2.9 million for Q2 2025 and $187,000 for Q1 2025.